High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer

Badovinac Črnjević, Tanja and Tanja, Badovinac Črnjević and Spagnoli, Giulio and Giulio, Spagnoli and Juretić, Antonio and Antonio, Juretić and Jakić-Razumović, Jasminka and Jasminka, Jakić-Razumović and Podolski, Paula and Paula, Podolski and Šarić, Nera and Nera, Šarić. (2012) High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer. Medical oncology, Vol. 29, H. 3. pp. 1586-1591.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6338095

Downloads: Statistics Overview


Recent studies indicate that ER/PR/HER-2-negative (triple-negative, TN) breast cancers may be "CTA-rich" tumors, suggesting the possibility of CTA-based cancer vaccines as a treatment option for patients bearing these tumors. MAGE-A10 together with NY-ESO-1 is probably the most immunogenic CTA, representing a potentially highly attractive target of active specific immunotherapies. Paraffin-embedded tumor sections were collected retrospectively from 165 breast cancer patients diagnosed between 2002 and 2003. Immunohistochemical staining for MAGE-A10 and NY-ESO-1 was performed. The expression of MAGE-A10 and NY-ESO-1 was correlated with other clinicopathological variables. MAGE-A10 expression (score </= 2+) was detected in 105/164 (64%), and NY-ESO-1 expression (score </= 2+) was observed in 14/164 (8.5%) patients. No correlation between MAGE-A10 and NY-ESO-1 expression and tumor size, tumor grade, Ki-67 and lymph nodes status was detectable. MAGE-A10 expression was significantly associated with ER-negative (P = 0.002), PR-negative (P = 0.002) and HER-2-negative (P = 0.044) tumors. We clearly showed that MAGE-A10 is frequently expressed in the group of TN patients, where the majority (85.7%) of tumors express this CTA. Because of limited therapeutic options for the triple-negative breast cancer, the frequent expression of MAGE-A10 CTA in these cancers may offer the opportunity for a much needed additional treatment for this group of patients.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Oncology Surgery (Spagnoli)
UniBasel Contributors:Spagnoli, Giulio C.
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:Springer US
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:04 Sep 2015 14:32
Deposited On:10 Apr 2015 09:14

Repository Staff Only: item control page